Valuation: LB Pharmaceuticals Inc

Market Cap 1.28B 1.15B 1.06B 956M 1.79B 122B 1.82B 12.58B 5.05B 63.97B 4.81B 4.7B 202B P/E 2026 *
-6.95x
P/E 2027 * -7.53x
Enterprise Value 901M 807M 743M 673M 1.26B 85.59B 1.28B 8.86B 3.55B 45.02B 3.38B 3.31B 142B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.76%
Yield 2026 *
-
Yield 2027 * -
1 day-1.12%
1 week+2.50%
Current month+3.44%
1 month+3.44%
3 months-2.93%
6 months+25.20%
Current year+78.35%
1 week 38.44
Extreme 38.445
41.24
1 month 33.13
Extreme 33.13
41.58
Current year 18.43
Extreme 18.43
50.16
1 year 14.32
Extreme 14.3166
50.16
3 years 13.36
Extreme 13.36
50.16
5 years 13.36
Extreme 13.36
50.16
10 years 13.36
Extreme 13.36
50.16
Manager TitleAgeSince
Chief Executive Officer 53 19/11/2024
Director of Finance/CFO 52 02/09/2026
Chief Tech/Sci/R&D Officer 54 14/09/2026
Director TitleAgeSince
Director/Board Member 76 01/07/2019
Director/Board Member 53 01/08/2023
Director/Board Member 53 19/11/2024
Date Insider Type Main position Quantity % Market Cap. Importance
9/10/26 Free

Chief Financial Officer

200,000 0.8911%
9/10/26 Free

Chief Technology Officer

200,000 0.8911%
30/7/26
Deep Track Capital LP
BuyCompany 286,205 0.8872%
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%+2.50%+143.86% - 1.28B
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.19%+7.04%+57.46%+206.32% 39.56B
Weighted average by Cap. +0.17%+5.43%+48.81%+186.13%

Financials

2026 *2027 *
Net sales - -
Net income -178M -160M -147M -133M -249M -16.92B -253M -1.75B -703M -8.9B -669M -654M -28.06B -201M -180M -166M -150M -281M -19.09B -286M -1.98B -793M -10.04B -755M -739M -31.68B
Net Debt -379M -340M -312M -283M -529M -36.01B -539M -3.73B -1.5B -18.94B -1.42B -1.39B -59.75B -479M -429M -395M -358M -669M -45.5B -681M -4.71B -1.89B -23.93B -1.8B -1.76B -75.48B
Projected Income Statement - Annual - LB Pharmaceuticals Inc
Logo LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Employees
49
Date Price Change Volume
30/10/26 USD 39.70 -1.12% 429,474
29/10/26 USD 40.15 +0.80% 400,678
28/10/26 USD 39.83 +0.48% 201,736
27/10/26 USD 39.64 +0.76% 236,345
26/10/26 USD 39.34 +1.58% 275,975
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - LB Pharmaceuticals Inc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
39.70USD
Average target price
58.00USD
Spread / Average Target
+46.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - LB Pharmaceuticals Inc
  1. Stock Market
  2. Stocks
  3. LBRX Stock